NCCN Guidelines® Insights Thyroid Carcinoma, Version 2.2018 Featured Updates to the NCCN Guidelines
NCCN Guidelines® Insights Thyroid Carcinoma, Version 2.2018 Featured Updates to the NCCN Guidelines
复制标题
NCCN Guidelines® Insights甲状腺癌，2.2018版NCCN指南的特色更新
DOI：
10.6004/jnccn.2018.0089
复制
发表时间：
2018-12-01
影响因子：
13.4
通讯作者：
Gurski, Lisa A.
中科院分区：
文献类型：
--
作者：
Haddad, Robert I.;Nasr, Christian;Gurski, Lisa A.
NCCN甲状腺癌指南为不同类型甲状腺癌的治疗提供了建议，包括乳头状癌、滤泡癌、Hurthle细胞癌、髓样癌和间变性癌。这些NCCN指南见解总结了近期指南更新后的小组讨论，包括分子检测在分化型甲状腺癌中的扩大作用，具有乳头状核特征的非侵袭性滤泡性甲状腺肿瘤的新病理诊断的意义，以及BRAF v600e突变间变性甲状腺癌的新靶向治疗选择。
The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hurthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E-mutated anaplastic thyroid carcinoma.